Intravesical administration with CaSR agonist ameliorated cystitis-induced bladder hyperactivity, which further suggested the promising potential of the urothelial CaSR as a pharmacotherapeutic target for bladder disorders. This evidence concerns the gene CASR and urinary bladder disorder.